Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants
NCT07577479Phase 1Active, not recruiting
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- May 2026
- Primary completion
- Jun 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised trial of BW-50218 (4 arms), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Primary endpoints: Incidence and Severity of Adverse Events and Serious Adverse Events at Day 360, Hematology results at Day 360 and 5 more. Started May 2026; status: active, not recruiting.
02
Drugs
BW-50218
Beyond the preview
Go deeper on NCT07577479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577479.